U.S., Jan. 22 -- ClinicalTrials.gov registry received information related to the study (NCT07353931) titled 'Efficacy and Safety of Eloralintide (LY3841136) in Participants With Osteoarthritis Knee Pain and Obesity or Overweight' on Jan. 16.
Brief Summary: The YDAN master protocol will support two independent studies, J3R-MC-YOA1 and J3R-MC-YOA2. Each study will investigate how well and safely Eloralintide (LY3841136) works in adults with obesity or overweight who have osteoarthritis (OA) of the knee with pain. Participation in the study will last about 75 weeks, including screening.
Study Start Date: Feb., 2026
Study Type: INTERVENTIONAL
Condition:
Osteoarthritis
Overweight or Obesity
Intervention:
DRUG: Eloralintide
Administered S...